These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 27504930)

  • 1. Enzymatic assays for detecting lactose and sucrose in urine to reveal intravenous drug abuse with emphasis on buprenorphine.
    Keltanen T; Mariottini C; Walta AM; Rahikainen AL; Ojanperä I
    Drug Test Anal; 2017 Jun; 9(6):949-952. PubMed ID: 27504930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring Intravenous Abuse of Methadone or Buprenorphine in Opiate Maintenance Treatment (OMT): A Simple and Fast LC-MS-MS Method for the Detection of Disaccharides in Urine Samples.
    Jungen H; Andresen-Streichert H; Müller A; Iwersen-Bergmann S
    J Anal Toxicol; 2017 Jan; 41(1):22-31. PubMed ID: 28130543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disaccharides in urine samples as markers of intravenous abuse of methadone and buprenorphine.
    Jungen H; Andresen-Streichert H; Müller A; Iwersen-Bergmann S
    J Anal Toxicol; 2013; 37(9):652-8. PubMed ID: 24099717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enzymatic assay for urine lactose in the assessment of recent intravenous abuse of buprenorphine.
    Keltanen TN; Heikman PK; Muhonen LH; Gunnar TO; Ojanperä IA
    Drug Test Anal; 2019 Sep; 11(9):1412-1418. PubMed ID: 31140750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous methadone application as a serious risk factor for an overdose death: methadone-related fatalities in Hamburg from 2007 to 2012.
    Iwersen-Bergmann S; Jungen H; Andresen-Streichert H; Müller A; Elakkary S; Püschel K; Heinemann A
    Int J Legal Med; 2014 Sep; 128(5):751-64. PubMed ID: 24859230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interpretation of urine drug testing results in patients using transdermal buprenorphine preparations for the treatment of chronic noncancer pain.
    Markman JD; Barbosa WA; Gewandter JS; Frazer M; Rast S; Dugan M; Nandigam K; Villareal A; Kwong TC
    Pain Med; 2015 Jun; 16(6):1132-6. PubMed ID: 25800409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Novel Enzyme Immunoassay for the Detection of Buprenorphine, Norbuprenorphine and Their Glucuronides in Urine.
    Schubert B; Pitterl F; Saxl B; Pavlic M
    J Anal Toxicol; 2019 Jun; 43(5):364-368. PubMed ID: 30753557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Definitive urine drug testing in office-based opioid treatment: a literature review.
    Barthwell AG; Allgaier J; Egli K
    Crit Rev Toxicol; 2018 Nov; 48(10):829-852. PubMed ID: 30794024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New psychoactive substances as part of polydrug abuse within opioid maintenance treatment revealed by comprehensive high-resolution mass spectrometric urine drug screening.
    Heikman P; Sundström M; Pelander A; Ojanperä I
    Hum Psychopharmacol; 2016 Jan; 31(1):44-52. PubMed ID: 26763789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre.
    Stimolo C; Favero VD; Zecchinato G; Buson R; Cusin D; Pellachin P; Simonetto P
    Clin Drug Investig; 2010; 30 Suppl 1():27-31. PubMed ID: 20450243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative testing of buprenorphine and norbuprenorphine to identify urine sample spiking during office-based opioid treatment.
    Suzuki J; Zinser J; Issa M; Rodriguez C
    Subst Abus; 2017; 38(4):504-507. PubMed ID: 28723256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parenteral buprenorphine-naloxone abuse is a major cause of fatal buprenorphine-related poisoning.
    Häkkinen M; Heikman P; Ojanperä I
    Forensic Sci Int; 2013 Oct; 232(1-3):11-5. PubMed ID: 24053859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and GC-MS validation of a highly sensitive recombinant G6PDH-based homogeneous immunoassay for the detection of buprenorphine and norbuprenorphine in urine.
    Wang G; Vincent M; Rodrigues W; Agrawal A; Moore C; Barhate R; Abolencia E; Coulter C; Soares J; Zheng YF; Taylor C; Morjana N
    J Anal Toxicol; 2007 Sep; 31(7):377-82. PubMed ID: 17725885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urinalysis-based comparative evaluation of pattern of use of dextropropoxyphene and buprenorphine among opioid-dependent subjects.
    Balhara YP; Jain R
    J Opioid Manag; 2012; 8(1):45-9. PubMed ID: 22479884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic switch to buprenorphine/naloxone from buprenorphine alone: clinical experience in an Italian addiction centre.
    Montesano F; Zaccone D; Battaglia E; Genco F; Mellace V
    Clin Drug Investig; 2010; 30 Suppl 1():13-9. PubMed ID: 20450241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of buprenorphine/naloxone in opioid-dependent patients: an Italian observational study.
    Magnelli F; Biondi L; Calabria R; Fiore A; Peluso E; Vonella D; Rota AG
    Clin Drug Investig; 2010; 30 Suppl 1():21-6. PubMed ID: 20450242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High prevalence of urine tampering in an office-based opioid treatment practice detected by evaluating the norbuprenorphine to buprenorphine ratio.
    Accurso AJ; Lee JD; McNeely J
    J Subst Abuse Treat; 2017 Dec; 83():62-67. PubMed ID: 29129197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous determination of opiates, methadone, buprenorphine and metabolites in human urine by superficially porous liquid chromatography tandem mass spectrometry.
    Lin HR; Chen CL; Huang CL; Chen ST; Lua AC
    J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Apr; 925():10-5. PubMed ID: 23507455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for drugs of abuse (II): Cannabinoids, lysergic acid diethylamide, buprenorphine, methadone, barbiturates, benzodiazepines and other drugs.
    Simpson D; Braithwaite RA; Jarvie DR; Stewart MJ; Walker S; Watson IW; Widdop B
    Ann Clin Biochem; 1997 Sep; 34 ( Pt 5)():460-510. PubMed ID: 9293303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical experience with fortnightly buprenorphine/naloxone versus buprenorphine in Italy: preliminary observational data in an office-based setting.
    Amato P
    Clin Drug Investig; 2010; 30 Suppl 1():33-9. PubMed ID: 20450244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.